Umirolimus: Difference between revisions

Revision as of 11:57, 9 February 2025

Umirolimus

Umirolimus is a pharmaceutical drug that acts as an immunosuppressant. It is a derivative of sirolimus, also known as rapamycin, and is used primarily in the context of drug-eluting stents to prevent restenosis in patients undergoing percutaneous coronary intervention.

Mechanism of Action

Umirolimus works by inhibiting the mammalian target of rapamycin (mTOR), a key regulatory kinase involved in cell proliferation, growth, and survival. By blocking mTOR, umirolimus effectively reduces the proliferation of smooth muscle cells in the arterial wall, which is a major factor in the development of restenosis.

Clinical Use

Umirolimus is primarily used in cardiology as a coating for drug-eluting stents. These stents are placed in coronary arteries to keep them open after procedures such as angioplasty. The drug coating helps to prevent the re-narrowing of the artery by inhibiting excessive tissue growth.

Development and Approval

Umirolimus was developed as part of efforts to improve the outcomes of coronary stenting procedures. It has been evaluated in various clinical trials to assess its efficacy and safety compared to other drug-eluting stents. The results have generally shown that umirolimus-coated stents are effective in reducing the incidence of restenosis.

Side Effects

As with other immunosuppressive agents, the use of umirolimus can be associated with certain side effects. These may include an increased risk of infection, delayed wound healing, and potential interactions with other medications. Patients receiving umirolimus-coated stents are monitored for these potential adverse effects.

Related Pages

References

@@ Line 1: / Line 1: @@
-'''Umirolimus''' is a [[drug]] used in [[drug-eluting stents]] to prevent [[restenosis]]. It is a semi-synthetic derivative of [[sirolimus]] and works by inhibiting [[cell proliferation]].
+== Umirolimus ==
-== Mechanism of action ==
+[[File:Umirolimus.svg|thumb|Chemical structure of Umirolimus]]
-Umirolimus inhibits the [[mammalian target of rapamycin]] (mTOR) pathway, which is a key regulator of cell growth and proliferation. By blocking this pathway, umirolimus prevents the proliferation of [[smooth muscle cells]] that can lead to restenosis.
-== Use in drug-eluting stents ==
+'''Umirolimus''' is a [[pharmaceutical drug]] that acts as an [[immunosuppressant]]. It is a derivative of [[sirolimus]], also known as rapamycin, and is used primarily in the context of [[drug-eluting stents]] to prevent [[restenosis]] in patients undergoing [[percutaneous coronary intervention]].
-Umirolimus is used in the [[BioMatrix]] drug-eluting stent system. This system uses a biodegradable polymer that releases umirolimus into the blood vessel wall over a period of several months. The slow release of the drug helps to prevent restenosis without causing the problems associated with permanent polymers.
-== Clinical trials ==
+== Mechanism of Action ==
-Several clinical trials have demonstrated the effectiveness of umirolimus in preventing restenosis. The LEADERS trial, for example, found that the BioMatrix stent was superior to a bare-metal stent in terms of preventing restenosis and major adverse cardiac events.
+Umirolimus works by inhibiting the [[mammalian target of rapamycin]] (mTOR), a key regulatory kinase involved in cell proliferation, growth, and survival. By blocking mTOR, umirolimus effectively reduces the proliferation of [[smooth muscle cells]] in the arterial wall, which is a major factor in the development of restenosis.
-== Side effects ==
+== Clinical Use ==
-As with all drugs, umirolimus can cause side effects. These can include [[pain]], [[inflammation]], and [[infection]]. However, these side effects are generally rare and the benefits of preventing restenosis typically outweigh the risks.
+Umirolimus is primarily used in [[cardiology]] as a coating for drug-eluting stents. These stents are placed in [[coronary arteries]] to keep them open after procedures such as [[angioplasty]]. The drug coating helps to prevent the re-narrowing of the artery by inhibiting excessive tissue growth.
-== See also ==
+== Development and Approval ==
+Umirolimus was developed as part of efforts to improve the outcomes of coronary stenting procedures. It has been evaluated in various clinical trials to assess its efficacy and safety compared to other drug-eluting stents. The results have generally shown that umirolimus-coated stents are effective in reducing the incidence of restenosis.
+== Side Effects ==
+As with other immunosuppressive agents, the use of umirolimus can be associated with certain side effects. These may include an increased risk of [[infection]], delayed wound healing, and potential interactions with other medications. Patients receiving umirolimus-coated stents are monitored for these potential adverse effects.
+== Related Pages ==
 * [[Sirolimus]]
 * [[Drug-eluting stent]]
-* [[Restenosis]]
+* [[Percutaneous coronary intervention]]
-* [[Mammalian target of rapamycin]]
+* [[Coronary artery disease]]
+== References ==
+{{Reflist}}
-[[Category:Drugs]]
+[[Category:Immunosuppressants]]
 [[Category:Cardiology]]
-[[Category:Pharmacology]]
-{{stub}}